Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reck

Showing results (1171-1180 of 1,518) with videos related to

Pageof 152
Sort By:
Cancer Chemotherapy and Pharmacology|May 4, 2018
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancerEgbert F Smit, Edward B Garon, Martin Reck, et al.
Acta Psychiatrica Scandinavica|January 5, 2007
Impulsiveness in obsessive-compulsive disorder: results from a family studyS Ettelt, S Ruhrmann, S Barnow, et al.
Plos One|April 26, 2014
Proteomic analysis of cattle tick Rhipicephalus (Boophilus) microplus saliva: a comparison between partially and fully engorged femalesLucas Tirloni, José Reck, Renata Maria Soares Terra, et al.
Future Oncology (London, England)|May 22, 2023
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic <i>EGFR</i>-mutated NSCLCHelena A Yu, James Chih-Hsin Yang, Hidetoshi Hayashi, et al.
The Lancet. Oncology|January 14, 2014
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialMartin Reck, Rolf Kaiser, Anders Mellemgaard, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2016
A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung CancerGerald Schmid-Bindert, Walburga Engel-Riedel, Martin Reck, et al.
Nature Materials|January 22, 2021
Self-repair protects microtubules from destruction by molecular motorsSarah Triclin, Daisuke Inoue, Jérémie Gaillard, et al.
The Oncologist|February 14, 2018
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung CancerJoachim von Pawel, David R Spigel, Thomas Ervin, et al.
British Journal of Cancer|April 15, 2010
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphismC-F Xu, B H Reck, Z Xue, et al.
Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc|July 1, 2009
Lung pathology and infectious agents in fatal feedlot pneumonias and relationship with mortality, disease onset, and treatmentsRobert W Fulton, K Shawn Blood, Roger J Panciera, et al.
Pageof 152

Showing results (1171-1180 of 1,518) with videos related to

Sort By:
Pageof 152
Cancer Chemotherapy and Pharmacology|May 4, 2018
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancerEgbert F Smit, Edward B Garon, Martin Reck, et al.
Acta Psychiatrica Scandinavica|January 5, 2007
Impulsiveness in obsessive-compulsive disorder: results from a family studyS Ettelt, S Ruhrmann, S Barnow, et al.
Plos One|April 26, 2014
Proteomic analysis of cattle tick Rhipicephalus (Boophilus) microplus saliva: a comparison between partially and fully engorged femalesLucas Tirloni, José Reck, Renata Maria Soares Terra, et al.
Future Oncology (London, England)|May 22, 2023
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic <i>EGFR</i>-mutated NSCLCHelena A Yu, James Chih-Hsin Yang, Hidetoshi Hayashi, et al.
The Lancet. Oncology|January 14, 2014
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialMartin Reck, Rolf Kaiser, Anders Mellemgaard, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2016
A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung CancerGerald Schmid-Bindert, Walburga Engel-Riedel, Martin Reck, et al.
Nature Materials|January 22, 2021
Self-repair protects microtubules from destruction by molecular motorsSarah Triclin, Daisuke Inoue, Jérémie Gaillard, et al.
The Oncologist|February 14, 2018
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung CancerJoachim von Pawel, David R Spigel, Thomas Ervin, et al.
British Journal of Cancer|April 15, 2010
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphismC-F Xu, B H Reck, Z Xue, et al.
Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc|July 1, 2009
Lung pathology and infectious agents in fatal feedlot pneumonias and relationship with mortality, disease onset, and treatmentsRobert W Fulton, K Shawn Blood, Roger J Panciera, et al.
Pageof 152